Global CAR T Cell Therapy Market Status, Trends and COVID-19 Impact Report 2021, Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends, and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider CAR T Cell Therapy market, and compares it with other markets., market definition, regional market opportunity, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, Digital Evidence Management market size forecast, market data & Graphs and Statistics, Tables, Bar &Pie Charts, and many more for business intelligence. Get complete Report (Including Full TOC, 100+ Tables & Figures, and Chart). – In-depth Analysis Pre & Post COVID-19 Market Outbreak Impact Analysis & Situation by Region.
The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Report Ocean.
The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.
Request To Download Sample of This Strategic Report :-https://reportocean.com/industry-verticals/sample-request?report_id=5124
This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer. The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.
The potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.
It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.
Get a Sample PDF copy of the report :-https://reportocean.com/industry-verticals/sample-request?report_id=5124
It can be seen that the business scenario of the market is dynamic and major companies are competing with each other to increase their market share in the major geographies of U.S. and Europe. For example, Novartis and Gilead came-up with 33 and 28 authorized centers respectively in U.S. Some of the major companies in this space such as Celgene are expected to file for FDA approvals for two more CAR-Ts lisocabtagene maraleucel in lymphoma and bb2121 (idecabtagene vicleucel) in myeloma.
Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.
Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.
Report Ocean has segmented the CAR-T Cell Therapy market report on the basis of Target Antigens, Indications, and Region
CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 – 2026)
CD19/CD22
BCMA (B-Cell Maturation Antigen)
Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Rα2, LewisY)
Request Full Report :-https://reportocean.com/industry-verticals/sample-request?report_id=5124
CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 – 2026)
Diffuse Large B-Cell Lymphoma (DLBCL)
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma (MM)
Follicular Lymphoma (FL)
Others
CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 – 2026)
U.S.
Europe
Japan
Rest of the World
Aim of the Report
- This study aims to determine the market size of various segments and countries with forecast values for next ten years.
- Within the regions and countries studied, the report covers both qualitative and quantitative aspects of the industry.
- It also provides detailed information about the crucial aspects such as drivers & challenges that will influence the market’s future growth.
- The report will also include investment opportunities in micro markets for stakeholders. In addition, an in-depth analysis of key players’ products and the competitive landscape.
What is the goal of the report?
-The market report presents the estimated size of the Healthcare market at the end of the forecast -period.
-The report also examines historical and current market sizes.
-During the forecast period, the report analyzes the growth rate, market size, and market valuation.
-The report presents current trends in the industry and the future potential of the North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa markets.
-The report offers a comprehensive view of the market based on geographic scope, market segmentation, and key player financial performance.
Full Report Description, TOC, Table of Figure, Chart, etc.-https://reportocean.com/industry-verticals/sample-request?report_id=5124
About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is a ‘one-stop solution’ for individuals, organizations, and industries that are looking for innovative market research reports.
Get in Touch with Us:
Report Ocean:
Email:sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 – UNITED STATES Tel: +1 888 212 3539 (US – TOLL FREE)
Website:https://www.reportocean.com/